Glutamate as a marker of cognitive function in schizophrenia: A proton spectroscopic imaging study at 4 tesla

Biological Psychiatry

Volumn 69, Issue 1, 2011, Pages 19-27

  Bustillo, Juan R ^a,b   Chen, Hongji ^a   Gasparovic, Charles ^a   Mullins, Paul ^c   Caprihan, Arvind ^e   Qualls, Clifford ^a   Apfeldorf, William ^a   Lauriello, John ^d   Posse, Stefan ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c BANGOR UNIVERSITY   (United Kingdom)

^d University of Missouri   (United States)

^e MIND RESEARCH NETWORK   (United States)

Author keywords

1H MRS; Cognition; Glutamate; Inositol; N acetylaspartate; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ASPARTIC ACID; CHOLINE; CHROMIUM; CREATINE; CREATINE PHOSPHATE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCINE; INOSITOL; INOSITOL DERIVATIVE; INSULIN; LACTIC ACID; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PHOSPHOETHANOLAMINE; SCYLLOINOSITOL; TAURINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID METABOLISM; ARTICLE; BRAIN CORTEX; BRAIN MAPPING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; WHITE MATTER;

ADULT; AGE FACTORS; ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; NERVE FIBERS, UNMYELINATED; NEUROPSYCHOLOGICAL TESTS; PROTONS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 78650034460     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.08.024     Document Type: Article

References (52)

1. M.F. Green, R.S. Kern, D.L. Braff, and J. Mintz Neurocognitive deficits and functional outcomes in schizophrenia: Are we measuring the right stuff? Schizophr Bull 26 2000 119 126
2. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 1995 998 1007
3. J. Theberge, R. Bartha, D.J. Drost, R.S. Menon, A. Malla, and J. Takhar Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers Am J Psychiatry 159 2002 1944 1946
4. J. Theberge, Y. Al-Semaan, P.C. Williamson, R.S. Menon, R.W. Neufeld, and N. Rajakumar Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS Am J Psychiatry 160 2003 2231 2233
5. P. Tibbo, C. Hanstock, A. Valiakalayil, and P. Allen 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia Am J Psychiatry 161 2004 1116 1118
6. L. Tebartz van Elst, G. Valerius, M. Buchert, T. Thiel, N. Rusch, and E. Bubl Increased prefrontal and hippocampal glutamate and concentration in schizophrenia: Evidence from a magnetic resonance spectroscopy study Biol Psychiatry 58 2005 724 730
7. L. Chang, J. Friedman, T. Ernst, K. Zhong, N.D. Tsopelas, and K. Davis Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: Implication for glial dysfunction Biol Psychiatry 62 2007 1396 1404
8. S. Wood, G.E. Berger, M. Wellard, T. Proffitt, M. McConchie, and D. Velakoulis 1H-MRS investigation of the medial temporal lobe in antipsychotic-nave and early-treated first episode psychosis Schizophr Res 102 2008 163 170
9. T. Shin'Ya, S. Satsuki, T. Kyoko, S. Sumiko, N. Shusuke, and I. Jun-ichi Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy Schizophr Res 108 2008 69 77
10. D. Ongur, J.E. Jensen, A. Prescot, C. Storkc, M. Lundyd, B. Cohen, and P. Renshaw Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania Biol Psychiatry 64 2008 718 726
11. M.E. Shenton, C.C. Dickey, M. Frumin, and R.W. McCarley A review of MRI findings in schizophrenia Schizophr Res 49 2001 1 52
12. J.A. Lieberman Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective Biol Psychiatry 46 1999 729 739
13. T.H. McGlashan Is active psychosis neurotoxic? Schizophr Bull 32 2006 609 613
14. S. Laughlin Neural energy consumption and the representation of mental events, Chapter 7 R.G. Schulman, D.L. Rothman, Brain Energetics and Neuronal Activity: Applications to fMRI and Medicine. 2004 Wiley West Sussex, England 113 115
15. S. Posse, R. Otazo, A. Caprihan, J. Bustillo, H. Chen, and P.G. Henry Proton echo planar spectroscopic imaging of j-coupled resonances in human brain at 3 and 4 Tesla Magn Reson Med 58 2007 236 244
16. R.G. Steen, R.M. Hamer, and J.A. Lieberman Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: A systematic review and meta-analysis Neuropsychopharmacology 30 2005 1949 1962
17. M.S. Buchsbaum, and E.A. Hazlett Positron emission tomography studies of abnormal glucose metabolism in schizophrenia Schizophr Bull 24 1998 343 364
18. S.W. Provencher Automatic quantitation of localized in vivo 1H spectra with LCModel NMR Biomed 14 2001 260 264
19. T. Ernst, R. Kreis, and B.D. Ross Absolute quantitation of water and metabolites in the human brain 1. Compartments and water J Magn Reson B 102 1993 1 8
20. C. Gasparovic, T. Song, D. Devier, H.J. Bockholt, A. Caprihan, and P.G. Mullins Use of tissue water as a concentration reference for proton spectroscopic imaging Magn Reson Med 55 2006 1219 1226
21. H.P. Hetherington, J.W. Pan, G.F. Mason, D. Adams, M.J. Vaughn, D.B. Twieg, and G.M. Pohost Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation Magn Reson Med 36 1996 21 29
22. D. Wechsler Wechsler Adult Intelligence Scale, Third Edition: Administration and Scoring Manual 1997 The Psychological Corporation and Harcourt Brace San Antonio, TX
23. D. Wechsler Wechsler Memory Scale 3rd ed. 1997 Psychological Corporation and Harcourt Brace San Antonio, TX
24. M.D. Lezak, D.B. Howleson, D.W. Loring, H.J. Hannay, and J.S. Fischer Neuropsychological Assessment 4th ed. 2004 Oxford University Press New York
25. G.S. Wilkinson Wide Range Achievement Test 3rd ed. 1993 Wide Range, Inc Wilmington, Delaware
26. N.C. Andreasen Scale for the Assessment of Positive Symptoms (SAPS) 1984 University of Iowa Iowa City
27. N.C. Andreasen Scale for the Assessment of Negative Symptoms (SANS) 1984 University of Iowa Iowa City
28. D. Addington, J. Addington, and B. Schissel A depression rating scale for schizophrenics Schizophr Res 3 1990 247 251
29. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side-effects Acta Psychiatr Scand Suppl 212 1970 11 19
30. T.R. Barnes A rating scale for drug-induced akathisia Br J Psychiatry 154 1989 672 676
31. W. Guy ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76338 1976 US Department of Health, Education and Welfare Washington, DC 534 537
32. N.C. Andreasen, M. Flaum, and S. Arndt The Comprehensive Assessment of Symptoms and History (CASH) An instrument for assessing diagnosis and psychopathology Arch Gen Psychiatry 49 1992 615 623
33. A. Pfefferbaum, E. Adalsteinsson, D. Spielman, E. Sullivan, and K. Lim In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging Magn Reson Med 41 1999 276 284
34. A. Maudsley, C. Domenig, V. Govind, A. Darkazanli, C. Studholme, K. Arheart, and C. Bloomer Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI) Magn Reson Med 61 2009 548 559
35. J. Neter, and W. Wasserman Applied Linear Statistical Models 1974 Richard D. Irwin, Inc Homewood, IL Chapter 11, Section 11.3
36. N.R. Schooler Anti-psychotic medications and schizophrenia: Their effects in acute and maintenance treatment of the illness R.L. Cromwell, C.R. Snyder, Schizophrenia: Origins, Processes, Treatment, and Outcome 1993 Oxford University Press New York 284 295
37. K.O. Lim, M. Hedehus, M. Moseley, A. de Crespigny, E.V. Sullivan, and A. Pferfferbaum Proton magnetic resonance imaging of cortical gray and white matter in schizophrenia Arch Gen Psychiatry 55 1998 346 352
38. A. Bertolino, S. Nawroz, V.S. Mattay, A.S. Barnett, J.H. Duyn, and C.T. Moonen Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopy imaging Am J Psychiatry 153 1996 1554 1563 (Pubitemid 26406165)
39. L.S. Kegeles, D.C. Shungu, S. Anjilvel, S. Chan, S.P. Ellis, and E. Xanthopoulos Hippocampal pathology in schizophrenia: Magnetic resonance imaging and spectroscopy studies Psychiatry Res 98 2000 163 175
40. C.Y. Tang, J. Friedman, D. Shungu, L. Chang, T. Ernst, and D. Stewart Correlations between difussion tensor imaging (DTI) and magnetic resonance spectroscopy (1H MRS) in schizophrenic patients and normal controls BMC Psychiatry 7 2007 25
41. J. Ventura, G. Helleman, A. Thames, V. Koellner, and K. Neuchterlein Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis Schizophr Res 113 2009 189 199
42. R.S. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, and J.M. Gold Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Arch Gen Psychiatry 64 2007 633 647
43. R. Buchanan, D. Javitt, S. Marder, N. Schooler, J. Gold, and R. McMahon The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am J Psychiatry 164 2007 1593 1602
44. P.J. Harrison The neuropathology of schizophrenia A critical review of the data and their interpretation Brain 122 1999 593 624
45. L. Glantz, and D. Lewis Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia Arch Gen Psychiatry 57 2000 65 73
46. L.D. Selemon, G. Rajkowska, and P.S. Goldman-Rakic Abnormally high neuronal density in the schizophrenic cortex Arch Gen Psychiatry 52 1995 805 819
47. C. Arango, C. Moreno, S. Martnez, M. Parellada, M. Desco, and D. Moreno Longitudinal brain changes in early-onset psychosis Schizophr Bull 34 2008 341 353
48. N.T. Glanville, D.M. Byers, H.W. Cook, M.W. Spence, and F.B. Palmer Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin Biochim Biophys Acta 1004 1989 169 179
49. R. Frey, D. Metzler, P. Fischer, A. Heiden, J. Scharfetter, E. Moser, and S. Kasper Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 Tesla J Psychiatr Res 32 1998 411 420
50. M. Valenzuela, and P. Sachdev Magnetic resonance spectroscopy in Alzheimer's disease Neurology 56 2001 592 598
51. J. Bustillo, L. Rowland, P. Mullins, R. Jung, H. Chen, and C. Qualls 1H-MRS at 4 Tesla in minimally treated early schizophrenia Mol Psychiatry 15 2010 629 636
52. E.H. Barker, G. Basso, P.B. Barker, M.A. Smith, and D.Horsk Bonekamp Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla J Magn Reson Imaging 27 2008 489 499